Vivimed Labs (NSE:VIVIMEDLAB) ROCE %: -12.71% (As of Dec. 2025)


NSE:VIVIMEDLAB Vivimed Labs Ltd NSE:VIVIMEDLAB
33 GF Score
Price ₹5.71
GF Value ₹2.57
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Vivimed Labs ROCE %?

Vivimed Labs NSE:VIVIMEDLAB -0.87% 33 ROCE % is -12.71% as of Dec. 2025. GuruFocus rates NSE:VIVIMEDLAB with a GF Score™ of 33/100 and a GF Value™ of ₹2.57 (Significantly Overvalued). The stock has 7 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Vivimed Labs's annualized ROCE % for the quarter that ended in Dec. 2025 was -12.71%.

Vivimed Labs  (NSE:VIVIMEDLAB) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Vivimed Labs ROCE % Related Terms

Vivimed Labs ROCE % Historical Data

* Premium members only.

The historical data trend for Vivimed Labs's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vivimed Labs ROCE % Chart

Vivimed Labs Annual Data
Trend Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.83 -2.86 -40.40 -8.03 -5.72

Vivimed Labs Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -4.22 -3.87 -3.84 -4.61 -12.71
NSE:VIVIMEDLAB
33GF Score
Vivimed Labs Ltd NSE:VIVIMEDLAB
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Vivimed Labs ROCE % Calculation

Vivimed Labs's annualized ROCE % for the fiscal year that ended in Mar. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Mar. 2025 )  (A: Mar. 2024 )(A: Mar. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Mar. 2025 )  (A: Mar. 2024 )(A: Mar. 2025 )
=-301.13/( ( (9509.11 - 4103.26) + (9208.34 - 4081.98) )/ 2 )
=-301.13/( (5405.85+5126.36)/ 2 )
=-301.13/5266.105
=-5.72 %

Vivimed Labs's ROCE % of for the quarter that ended in Dec. 2025 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Dec. 2025 )  (Q: Sep. 2025 )(Q: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Dec. 2025 )  (Q: Sep. 2025 )(Q: Dec. 2025 )
=-622/( ( (9239.94 - 4346.01) + (0 - 0) )/ 1 )
=-622/( ( 4893.93 + 0 )/ 1 )
=-622/4893.93
=-12.71 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2025) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of -12.71% mean?
Vivimed Labs (NSE:VIVIMEDLAB) has a ROCE % of -12.71% as of Dec. 2025.
Is Vivimed Labs' ROCE % too high?
Vivimed Labs' current ROCE % is -12.71%. Overall, Vivimed Labs has a GF Score™ of 33/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Vivimed Labs' ROCE % compare to ZTS?
Vivimed Labs' ROCE % of -12.71% can be compared against companies in the Drug Manufacturers industry. The industry median ROCE % is 7.00. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Drug Manufacturers company?
The median ROCE % among Drug Manufacturers companies is 7.00, based on 958 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median ROCE % is 7.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vivimed Labs's current ROCE % is -12.71%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vivimed Labs stock overvalued right now?
Based on GuruFocus' analysis, Vivimed Labs (NSE:VIVIMEDLAB) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹2.57, compared to a current price of ₹5.71 — trading 122.2% above its estimated fair value. The current ROCE % is -12.71%. Vivimed Labs' overall GF Score™ is 33/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Vivimed Labs (NSE:VIVIMEDLAB), the current ROCE % is -12.71% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Vivimed Labs (NSE:VIVIMEDLAB) Overvalued in 2026?

Based on GuruFocus' analysis, Vivimed Labs stock appears to be overvalued. The current stock price of ₹5.71 is trading 122.2% above its estimated GF Value™ of ₹2.57. GuruFocus considers Vivimed Labs to be Significantly Overvalued.

Key valuation signals for NSE:VIVIMEDLAB:

  • ROCE %: -12.71%
  • GF Value™: ₹2.57 vs. price of ₹5.71 (122.2% above fair value)
  • GF Score™: 33/100 with 7 warning signs

No single metric tells the full story. See the NSE:VIVIMEDLAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Vivimed Labs Business Description

Other Exchanges 532660:India
Address Green Lands, Beside The Plaza Hotel, D.No. 6-3-866/1/G1, 3rd & 4th Floor, GMR Towers, Begumpet, Hyderabad, TG, IND, 500016
Vivimed Labs Ltd is an India-based company that is engaged in the Business of Active pharmaceutical ingredients, Intermediates, Nutraceutical ingredients, CDMO Finished Dosage Formulation, Specialty Chemicals, and Retail Branded Formulation manufacturing. The company has three reportable segments: the Speciality Chemicals Business, the Pharma Business, and others. The majority of revenue is earned through the Pharma business.
33GF Score

Get the complete analysis for NSE:VIVIMEDLAB

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹5.71
Price
₹2.57
GF Value